10-KPeriod: FY2024

BRISTOL MYERS SQUIBB CO Annual Report, Year Ended Dec 31, 2024

Filed February 12, 2025For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb (BMY) has filed its 2024 10-K, providing a comprehensive overview of its business, financial performance, and strategic direction. The report highlights the company's ongoing efforts in research and development, product portfolio management, and its approach to navigating the complex regulatory and competitive landscape within the pharmaceutical industry. Investors should pay close attention to the company's pipeline, potential market access challenges, and its strategies for maintaining long-term growth and shareholder value amidst evolving healthcare dynamics. The filing details the company's financial condition and results of operations, offering insights into revenue drivers, cost structures, and cash flow generation. Management's Discussion and Analysis is expected to provide crucial context on the factors influencing BMY's performance, including the impact of key product sales, patent expirations, and strategic investments. Furthermore, the report addresses risk factors, legal proceedings, and corporate governance, providing a holistic view for stakeholders assessing the company's overall health and future prospects.

Financial Highlights

56 data points
Beta

Revenue

$48.30B

71.1% Gross Margin

Net Income

-$8.95B

-18.5% Net Margin

EPS (Diluted)

$-4.41

Total Assets

$92.60B

Cash & Equivalents

$10.35B

Free Cash Flow

$13.94B

Financial Statements
Beta
Revenue$48.30B
Cost of Revenue$13.97B
Gross Profit$34.33B
R&D Expenses$11.16B
SG&A Expenses$8.41B
Operating Expenses$56.68B
Net Income-$8.95B
EPS (Basic)$-4.41
EPS (Diluted)$-4.41
Shares Outstanding (Basic)2.03B
Shares Outstanding (Diluted)2.03B

Key Highlights

  • 1The 10-K details Bristol Myers Squibb's business operations, encompassing product development, intellectual property, research and development initiatives, and go-to-market strategies.
  • 2Key sections include the company's approach to acquisitions, divestitures, licensing, and other strategic arrangements aimed at portfolio enhancement.
  • 3The report provides an in-depth look at BMY's products, including information on intellectual property, product exclusivity, and the competitive landscape they operate within.
  • 4Management's Discussion and Analysis of Financial Condition and Results of Operations (Item 7) will offer critical insights into the company's financial performance and operational drivers for the fiscal year 2024.
  • 5Consolidated Financial Statements (Item 8) will present the audited financial results, including statements of earnings, balance sheets, and cash flows, essential for financial health assessment.
  • 6The filing addresses significant risk factors (Item 1A) that could impact the company's future performance, including regulatory, market, and operational risks.
  • 7Information on human capital management and resources (under Item 1) highlights the company's focus on its workforce and organizational capabilities.

Frequently Asked Questions

The 10-K filing, specifically in Item 7 (Management's Discussion and Analysis of Financial Condition and Results of Operations) and Item 8 (Financial Statements and Supplementary Data), will detail the company's revenue streams. Investors should look for information on sales performance of key blockbuster drugs, contributions from newer products, and any impact from product exclusivity periods.

Item 1 (Business) of the 10-K typically outlines BMY's R&D strategy and therapeutic areas of focus. Investors can find information on the progress of drugs in various stages of clinical development, upcoming regulatory submissions, and any significant advancements or setbacks in their pipeline.

Item 1A (Risk Factors) provides a comprehensive list of potential risks that could adversely affect the company's business, financial condition, or results of operations. This includes risks related to clinical trial failures, regulatory approvals, competition, patent expirations, pricing pressures, and macroeconomic factors.

The Consolidated Statements of Cash Flows (Item 8) and the Management's Discussion and Analysis (Item 7) will provide details on the company's cash generation, capital expenditures, debt levels, and financing activities. This section is crucial for understanding BMY's liquidity and its ability to fund its operations, R&D, and potential strategic initiatives.